Genmab's Third Quarter 2026 Financial Results - ADC THERAPEUTICS SA

Explicit Guidance:

• FY2026 Revenue: Maintained guidance range of $4.325 billion to $4.525 billion (19% growth at midpoint); expect revenue to land in the upper part of the range due to first-nine-month performance.
• FY2026 OpEx: Full-year investment plan unchanged; expected range $2.81 billion to $2.95 billion, with a midpoint target of ~$2.88 billion. Q4 OpEx expected to "step up significantly" due to manufacturing, clinical, and launch readiness activities.
• FY2026 Adjusted Operating Profit: Target range $1.065 billion to $1.35 billion; expect the final figure to end above the midpoint (>$1.2 billion) given revenue in the upper range and OpEx near the midpoint.
• Effective Tax Rate: FY2026 YTD rate was 3.4%; rate is expected to normalize over the next 12 to 18 months following integration of Maris.
• Balance Sheet: Committed to reducing gross leverage to below 3x by the end of FY2027.

Business-Segment Outlook:

• Epkinley: Expects strong uptake in 2027 upon approval for first-line DLBCL (DLBCL-1 trial), aiming to establish it as the "core therapy in B-cell malignancies." Sales trajectory aims to reach > $3 billion peak annual sales. Uptake expected to drive from academic sites into the community, mirroring second-line FL rollout.
• RENAS: Ambition to become the "best, first, and broadest in class" for gynecologic oncology. After positive Phase 3 (RAIN FALL-02) in platinum-resistant ovarian cancer, expansion planned into endometrial cancer (including first-line induction and maintenance settings). Peak sales target remains > $2 billion.
• Pitocentumab: Confirmed > $3 billion peak sales potential. Launch readiness is a primary focus for FY2027. The asset is positioned as a "best-in-class" option in first-line head and neck cancer; Phase 3 readouts for second- and third-line settings expected in Q1 2027.
• Colorectal Cancer (CRC): Pito is already in Phase 3 trials for CRC. Management views the CRC opportunity as potentially "larger than head and neck" due to high unmet need. Data maturity expected in the next 12-24 months.
• Portfolio Growth: Non-Darzalex/non-Epkinley portfolio grew 30% YoY in the first nine months; revenue base becoming "more diversified and durable."

Market and Competitive Outlook:

• First-Line DLBCL: Management views the $0.49 hazard ratio in Epkinley vs. R-CHOP as "unprecedented" (scale of positivity not seen in 25 years), positioning it to replace R-CHOP as the new standard of care.
• Competitive Positioning: Epkinley holds a "time advantage" over competitor (Polatuximab + R-CHOP) which is expected to read out end of next year. Differentiation includes subcutaneous administration, dual indication, and community care ease.
• Head and Neck: Pito's data (OS HR 0.5, ORR) anchors it as the first positive Phase 3 in first-line in nearly a decade, addressing a "long overdue" setting.
• Ovarian/Endometrial: RENA-S is positioned to capture value across platinum-resistant and platinum-sensitive settings, as well as endometrial cancer, leveraging a strong existing gynecologic footprint (TIVDAC).

Macro / Industry Outlook:

• Regulatory/Approval Strategy: RENA-S endometrial filing strategy likely to be based on Phase 3 results (aligned with prior PIDOC approach).
• Safety/Durability: Pito safety profile (skin-toxicity distinct from competitor Amivantamab) is viewed as a key differentiator translating to better durability and potential for subcutaneous formulation (currently in Phase 2/3).
• Patent/Royalty Concerns: No specific timeline provided for Darzalex royalty expiration impact, but management expresses high conviction that new assets (Epkinley, RENA-S, Pito) will drive growth to offset any potential erosion.

Strategic Initiatives:

• Launch Readiness: Significant Q4 2026 investment planned for manufacturing, clinical development, and launch readiness specifically for RENA-S and Pitocentumab.
• R&D Pipeline Expansion: Moved four new antibody-based programs into the clinic this year (two bispecifics, two ADCs); two more programs expected to enter the clinic by end of 2026.
• M&A/Partnerships: Currently focusing capital on maximizing late-stage programs (internal and acquired) rather than new large acquisitions. Active engagement on combination partnerships (e.g., recent INSIGHT partnership) is ongoing.
• Events: Annual virtual R&D update and ASH data review scheduled for December 16, 2026.

Risks and Headwinds to Outlook:

• Trial Immaturity: OS data for Epkinley's frontline DLBCL trial is described as "totally immature" with only 10 months of follow-up; management expects hazard ratio to improve with longer follow-up.
• Regulatory Uncertainty: Reliance on Phase 3 data for regulatory filing (e.g., RENA-S endometrial) carries execution risk.
• Operational Execution: Q4 OpEx is expected to "step up significantly"; any failure in launch readiness or manufacturing could impact timelines.
• Market Adoption: Uptake in first-line DLBCL depends on successful transition from community to academic settings and payer approvals.

Management Tone on the Future:

• Confidence: High conviction regarding 2026 and 2027 profitability and growth. Language used includes "unprecedented," "remarkable," "best-in-class," and "transformative."
• Strategic Discipline: Repeated emphasis on balancing aggressive investment in late-stage assets with strong operating profit and de-leveraging (target <3x gross leverage).
• Momentum: Management expresses being "energized" by the Phase 3 readouts, viewing them as setting up multi-billion dollar launches in 2027.
• Guidance Stability: No changes to full-year guidance; confident in delivering on 2027 commitments (profit growth and deleveraging).

Miscellaneous:

• Q&A Insight: Management confirmed RENA-S Phase 3 data will likely support the filing for endometrial cancer, though no specific timeline for filing was given other than "actively planning engagement."
• Subcutaneous Pito: Subcutaneous formulation development is ongoing (partnered with Allozyme) but specific filing support details remain premature; expected to be a lifecycle management driver.
• Pivot to Community: Strategy heavily favors shifting treatment sites to the community (where 25+ years of experience exists) via subcutaneous options and dual indications.